150 related articles for article (PubMed ID: 17495978)
1. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.
Schwemmlein M; Stieglmaier J; Kellner C; Peipp M; Saul D; Oduncu F; Emmerich B; Stockmeyer B; Lang P; Beck JD; Fey GH
Leukemia; 2007 Jul; 21(7):1405-12. PubMed ID: 17495978
[TBL] [Abstract][Full Text] [Related]
2. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
Stieglmaier J; Bremer E; Kellner C; Liebig TM; ten Cate B; Peipp M; Schulze-Koops H; Pfeiffer M; Bühring HJ; Greil J; Oduncu F; Emmerich B; Fey GH; Helfrich W
Cancer Immunol Immunother; 2008 Feb; 57(2):233-46. PubMed ID: 17665197
[TBL] [Abstract][Full Text] [Related]
3. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
4. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
5. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
8. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
9. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
10. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
[TBL] [Abstract][Full Text] [Related]
11. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
12. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
[TBL] [Abstract][Full Text] [Related]
13. Chimeric fusion proteins--Pseudomonas exotoxin-based.
Kreitman RJ
Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
[TBL] [Abstract][Full Text] [Related]
14. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
15. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
Gunther R; Chelstrom LM; Tuel-Ahlgren L; Simon J; Myers DE; Uckun FM
Blood; 1995 May; 85(9):2537-45. PubMed ID: 7537120
[TBL] [Abstract][Full Text] [Related]
16. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
17. [Targeted killing of the Nalm-6 cells with 2E8-Genistein immunotoxin and its mechanism].
Chen YH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Qian BQ; Xu WQ; Ning BT
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):57-61. PubMed ID: 19573385
[TBL] [Abstract][Full Text] [Related]
18. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human CD19-ligand protein as a potent anti-leukaemic agent.
Uckun FM; Sun L; Qazi S; Ma H; Ozer Z
Br J Haematol; 2011 Apr; 153(1):15-23. PubMed ID: 21323891
[TBL] [Abstract][Full Text] [Related]
20. Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.
Tang J; Li J; Zhu X; Yu Y; Chen D; Yuan L; Gu Z; Zhang X; Qi L; Gong Z; Jiang P; Yu J; Meng H; An G; Zheng H; Yang L
Oncotarget; 2016 Jun; 7(23):34070-83. PubMed ID: 27083001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
